Esperion Therapeutics Inc
- Country
- 🇨🇷Costa Rica
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 240
- Market Cap
- $335.5M
- Website
- http://www.esperion.com
Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
- Conditions
- Healthy Lactating Women
- Interventions
- Drug: Bempedoic Acid 180 MG Oral TabletDrug: Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06021951
- Locations
- 🇺🇸
PPD Development, Las Vegas Research Unit, Las Vegas, Nevada, United States
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05694260
- Locations
- 🇪🇸
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell, Barcelona, Spain
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Providere Research Inc, West Covina, California, United States
Bempedoic Acid Pregnancy Surveillance Program
- Conditions
- PregnancyHyperlipidemias
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05103254
- Locations
- 🇺🇸
Evidera, PPD business unit, Morrisville, North Carolina, United States
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
- Conditions
- DiabetesDiabetes Mellitus, Type 2Cholesterolemia
- Interventions
- Drug: Bempedoic acid + Ezetimibe FDC Oral TabletDrug: Placebo oral capsuleDrug: Placebo Oral Tablet
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03531905
- Locations
- 🇺🇸
Clinical Trials Research, Lincoln, California, United States
🇺🇸FInlay Medical Research, Miami, Florida, United States
🇺🇸L-MARC Research Center, Louisville, Kentucky, United States
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
- Conditions
- Hyperlipidemias
- Interventions
- Combination Product: Bempedoic Acid + Ezetimibe Fixed-Dose CombinationDrug: Placebos
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT03337308
- Locations
- 🇺🇸
Foundation Cardiology, Nashua, New Hampshire, United States
🇺🇸PMG Research of Knoxville, Knoxville, Tennessee, United States
🇺🇸PMG Research of McFarland, Ames, Iowa, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03193047
- Locations
- 🇺🇸
L-MARC Research Center, Louisville, Kentucky, United States
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
- Conditions
- HypercholesterolemiaAtherosclerotic Cardiovascular Disease
- Interventions
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 1462
- Registration Number
- NCT03067441
- Locations
- 🇺🇸
Jedidiah Clinical Research, Tampa, Florida, United States
🇺🇸L-MARC Research Center, Louisville, Kentucky, United States
🇺🇸Sentral Clinical Research Services, Cincinnati, Ohio, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03051100
- Locations
- 🇺🇸
PMG Research of Rocky Mount, Rocky Mount, North Carolina, United States
🇺🇸PMG Research of Raleigh, Raleigh, North Carolina, United States
🇺🇸Hampton Roads Center for Clinical Research, Virginia Beach, Virginia, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
- Conditions
- HypercholesterolemiaAtherosclerosisStatin Adverse Reaction
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 269
- Registration Number
- NCT03001076
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
- Conditions
- Cardiovascular DiseasesStatin Adverse Reaction
- Interventions
- Drug: Bempedoic acid 180 mg tabletDrug: Matching placebo tablet
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 13970
- Registration Number
- NCT02993406
- Locations
- 🇺🇸
Seton Heart Institute, Austin, Texas, United States